Exagen
Exagen Inc. (NASDAQ: XGN) is a commercial-stage diagnostics company that develops and commercializes the AVISE testing portfolio, proprietary autoimmune rheumatic disease tests based on Cell-Bound Complement Activation Products (CB-CAPs) technology, serving rheumatologists, biopharma partners, and academic medical centers through its CLIA-certified laboratory in Vista, California.
- Company typePublic
- Founded2011
- HeadquartersVista, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Exagen does
Exagen Inc. (NASDAQ: XGN) is a publicly traded commercial-stage life sciences company that develops and commercializes proprietary diagnostic tests for autoimmune rheumatic diseases, primarily serving rheumatologists, biopharmaceutical companies, and academic medical centers. The company's core offering is the AVISE testing portfolio, anchored by AVISE CTD and AVISE Lupus, which leverage its proprietary Cell-Bound Complement Activation Products (CB-CAPs) technology—a platform that measures hydrolyzed complement activation byproducts (EC4d, BC4d, TC4d) bound to circulating erythrocytes, platelets, and lymphocytes. Cell binding confers marker stability for the life of the cells, providing differentiated diagnostic accuracy (AUC of 0.90, specificity above 98%) and the ability to identify approximately 25% more SLE patients missed by conventional serologic tests alone.
Exagen generates revenue primarily on a per-test basis through healthcare provider orders fulfilled at its CAP-accredited, CLIA-certified clinical laboratory in Vista, California. The Q1 2026 average selling price was $444 per test (+6% YoY), with full-year 2025 revenue of $66.6 million (20% YoY growth) and 2026 guidance of $70-73 million. Distribution is sales-led through a rheumatology-focused sales team targeting over 7,500 ordering providers, supplemented by biopharma partnerships (AbbVie, GSK, Janssen, Horizon Therapeutics, Immunovant, UCB) for clinical trial support and commercialization collaborations. The product line spans the continuum of autoimmune care—diagnosis (AVISE Lupus, AVISE CTD), disease activity monitoring (AVISE SLE Monitor), prognosis (AVISE SLE Prognostic), therapeutic drug monitoring (AVISE MTX, AVISE HCQ), and adjacent indications (AVISE APS, AVISE Vasculitis AAV, AVISE Anti-CarP), with recent expansions into anti-PAD4 and seronegative RA markers.
The company has accumulated a substantial clinical data asset exceeding 1.5 million analyzed data points across over 800,000 unique patients and 20+ years of operation, with over 1 million patients tested since the 2012 AVISE Lupus launch. Clinical validation is supported by more than 300 peer-reviewed publications and a 2026 systematic review in Lupus Science & Medicine. The company deploys AI/ML through a DataRobot partnership for predictive modeling and pattern recognition across its biomarker data portfolio. Despite top-line growth, Exagen reported a 2025 net loss of approximately $20 million against $32.2 million in cash, prompting recent capital raises including a $25 million Perceptive Advisors-led round in April 2025 and an additional $20.2 million round in May 2025. Founded in 2011 and headquartered in Vista, California, Exagen is led by CEO John Aballi (since October 2022) and Executive Chair Tina Nova, PhD.
Exagen firmographics
Firmographics- Name
- Exagen
- Legal name
- Exagen Inc.
- Website
- https://exagen.com
- Company type
- Public
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Exagen Inc. (NASDAQ: XGN) is a commercial-stage diagnostics company that develops and commercializes the AVISE testing portfolio, proprietary autoimmune rheumatic disease tests based on Cell-Bound Complement Activation Products (CB-CAPs) technology, serving rheumatologists, biopharma partners, and academic medical centers through its CLIA-certified laboratory in Vista, California.
- Ownership category
- akta.pro rank
Exagen industry classification
Industry- Product category
- Autoimmune Diagnostic Testing
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Autoimmune, Allergy & Specialized Immunology Diagnostics (HLAHAAAK)
- akta.pro secondary industries
- IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Autoimmune & Allergy Diagnostics (HLAAALAK), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
Keywords
Where Exagen is headquartered
LocationHeadquarters
- HQ city
- Vista
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Exagen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- AVISE Diagnostic Testing: Exagen generates revenue primarily from selling its AVISE diagnostic tests (AVISE CTD, AVISE Lupus, AVISE SLE Monitor, AVISE SLE Prognostic, AVISE APS, AVISE MTX, AVISE HCQ, AVISE Vasculitis AAV, AVISE Anti-CarP) to healthcare providers and rheumatologists. Revenue is generated per test, with Q1 2026 average selling price of $444 per test, a 6% increase year-over-year. The company reports record quarterly revenues ($17.3M Q1 2026) and full-year 2025 revenue of $66.6M, up 20% year-over-year.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Per-test laboratory diagnostic services |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Exagen product offering
Product offeringCore offering
Exagen is a commercial-stage life sciences company that develops and performs proprietary AVISE diagnostic tests for autoimmune rheumatic diseases through its CAP-accredited, CLIA-certified clinical laboratory in Vista, California. The portfolio centers on AVISE CTD and AVISE Lupus, powered by the company's proprietary Cell-Bound Complement Activation Products (CB-CAPs) biomarker technology, and is supplemented by disease monitoring, prognostic, drug monitoring, vasculitis, and rheumatoid arthritis testing products sold primarily to rheumatologists, healthcare providers, and biopharma companies on a per-test basis.
Product overview
Exagen is a commercial-stage life sciences company offering the AVISE diagnostic testing portfolio, a suite of products based on proprietary Cell-Bound Complement Activation Products (CB-CAPs) technology. The core offering centers on AVISE CTD (connective tissue disease diagnostic) and AVISE Lupus (SLE diagnostic), supported by monitoring, prognostic, and drug monitoring add-on tests including AVISE SLE Monitor, AVISE SLE Prognostic, AVISE APS, AVISE MTX, and AVISE HCQ. Additional products include AVISE Vasculitis AAV for ANCA-associated vasculitis and AVISE Anti-CarP for rheumatoid arthritis risk stratification. All tests are performed in Exagen's CAP-accredited, CLIA-certified laboratory in Vista, California.
Differentiator
Problem solved
Functional benefit
Brands
- AVISE: Next-generation autoimmune testing product line including AVISE CTD, AVISE Lupus, AVISE SLE Monitor, AVISE SLE Prognostic, AVISE APS, AVISE MTX, AVISE HCQ, AVISE Vasculitis AAV, and AVISE Anti-CarP tests
- AVISE CTD
- AVISE Lupus
- AVISE SLE Monitor
- AVISE SLE Prognostic
- CB-CAPs
Products and services
- AVISE CTD Comprehensive diagnostic tool powered by CB-CAPs technology designed to help distinguish patients with connective tissue disease (CTD) or similar diseases with overlapping symptoms. Includes SLE and connective tissue disease testing with markers such as EC4d, BC4d, and TC4d. Used by rheumatologists for differential diagnosis.
- AVISE Lupus SLE (Systemic Lupus Erythematosus) diagnostic test that uses CB-CAPs biomarkers to uniquely identify approximately 25% of SLE patients who would be missed by conventional serologic tests alone, with AUC of 0.90 and specificity above 98%. Used by rheumatologists for SLE diagnosis.
- AVISE SLE Monitor Laboratory monitoring tool leveraging Erythrocyte-Bound C4d (EC4d) to help assess disease activity and monitor patients with SLE over time. Used by rheumatologists for ongoing SLE patient management.
- AVISE SLE Prognostic 10-marker prognostic panel developed to assess patient risk for Thrombosis, Cardiovascular events, Lupus Nephritis, and Neuropsychiatric Lupus. Includes anti-C1q biomarker for renal activity assessment. Used by rheumatologists for risk stratification.
- AVISE APS Advanced antiphospholipid syndrome diagnostic test composed of biomarkers including anti-phosphatidylserine/prothrombin (PS/PT), anti-cardiolipin, and anti-β2-Glycoprotein 1 to assess patient risk for APS and thrombosis. Used by rheumatologists for APS diagnosis.
- AVISE MTX Methotrexate Polyglutamate Measuring Test providing accurate measurement of active MTX metabolites (MTXPGs) to help physicians assess patient exposure to methotrexate therapy and inform dosing decisions. Used by rheumatologists for therapeutic drug monitoring.
- AVISE HCQ Hydroxychloroquine blood level test measuring drug levels in whole blood to help physicians assess patient compliance, disease flare risk, and therapeutic decision making for SLE patients on HCQ therapy. Used by rheumatologists for therapeutic drug monitoring.
- AVISE Vasculitis AAV Complete panel of ANCA-associated markers for swift and accurate assessment of ANCA-associated vasculitis (AAV) disease state, including c-ANCA, p-ANCA, anti-PR3, anti-MPO, and anti-GBM assays. Used by rheumatologists for vasculitis diagnosis.
- AVISE Anti-CarP Blood test measuring anti-carbamylated protein antibodies to identify rheumatoid arthritis patients with increased risk for erosive joint damage, useful for patients negative for traditional biomarkers RF and ACPA. Used by rheumatologists for RA risk stratification.
- AVISE Anti-PAD4 Anti-PAD4 antibody biomarker test launched in October 2025 supporting rheumatoid arthritis diagnostics. Used by rheumatologists for RA diagnosis.
- Biopharma and Clinical Trial Services Customizable diagnostic testing services for biopharmaceutical companies developing autoimmune disease therapeutics. Includes biomarker discovery, clinical trial patient selection and monitoring, technology transfer, and post-FDA approval real-world evidence generation. Used by biopharma companies and CROs.
Quantifiable outcome
- AVISE Lupus identified approximately 25% more systemic lupus erythematosus patients than conventional serologic tests alone
- +4 more outcomes
Companies that use Exagen
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Exagen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature9 records
Exagen partnerships and signals
Strategic signalPartnerships
17 partnerships are on record, tiered core.
- AbbViecoreBiopharma partner collaborating on autoimmune disease research and development. AbbVie is one of Exagen's key biopharma partners listed on their collaborations page.
- GSKcoreBiopharma partner collaborating on autoimmune disease research and development. GSK is listed as a biopharma partner on Exagen's collaborations page.
- Horizon TherapeuticscoreBiopharma partner collaborating on autoimmune disease research and development.
- ImmunovantcoreBiopharma partner collaborating on autoimmune disease research and development.
- JanssencoreBiopharma partner collaborating on autoimmune disease research and development.
- UCBcoreBiopharma partner collaborating on autoimmune disease research and development.
- Brigham and Women's HospitalcoreAcademic collaborator in autoimmune disease research and diagnostic development.
- Johns Hopkins MedicinecoreAcademic collaborator in autoimmune disease research and diagnostic development.
- Hospital for Special SurgerycoreAcademic collaborator in autoimmune disease research and diagnostic development.
- Duke UniversitycoreAcademic collaborator in autoimmune disease research and diagnostic development.
- NYU Langone HealthcoreAcademic collaborator in autoimmune disease research and diagnostic development.
- Northwestern University Feinberg School of MedicinecoreAcademic collaborator in autoimmune disease research and diagnostic development.
- Emory UniversitycoreAcademic collaborator in autoimmune disease research and diagnostic development.
- David Geffen School of Medicine at UCLAcoreAcademic collaborator in autoimmune disease research and diagnostic development.
- Montefiore Health SystemcoreAcademic collaborator in autoimmune disease research and diagnostic development.
- Northwell HealthcoreAcademic collaborator in autoimmune disease research and diagnostic development.
- AdventHealthcoreAcademic collaborator in autoimmune disease research and diagnostic development.
Scale indicators15 records
Recent moves6 records
Expansion highlights5 records
Exagen competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights7 records
Customer concentration
Exagen social profiles
Digital presenceExagen compliance and trust
Trust signalCompliance3 records
Exagen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Exagen leadership team
Management profileNumber of profiles
Profiles16 records
Exagen funding detail
Funding detailFunding overview
Funding rounds26 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Exagen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Exagen
What does Exagen do?
Exagen is a commercial-stage life sciences company that develops and performs proprietary AVISE diagnostic tests for autoimmune rheumatic diseases through its CAP-accredited, CLIA-certified clinical laboratory in Vista, California. The portfolio centers on AVISE CTD and AVISE Lupus, powered by the company's proprietary Cell-Bound Complement Activation Products (CB-CAPs) biomarker technology, and is supplemented by disease monitoring, prognostic, drug monitoring, vasculitis, and rheumatoid arthritis testing products sold primarily to rheumatologists, healthcare providers, and biopharma companies on a per-test basis.
Is Exagen a public or private company?
Exagen is a public company. It is classified as public and is currently operating.
When was Exagen founded?
Exagen was founded in 2011. It employs 101 to 250 people.
Where is Exagen based?
Exagen is headquartered in Vista, United States, in the North America region.
How does Exagen make money?
One revenue line is on record: AVISE Diagnostic Testing.
Does Exagen have an API?
No public API is recorded for Exagen.
What industry is Exagen in?
Exagen's product category is Autoimmune Diagnostic Testing. Its primary akta.pro industry code is HLAHAAAK, Autoimmune, Allergy & Specialized Immunology Diagnostics, with a secondary code of HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument). Its NAICS code is 325413 and its SIC code is 2835.